Investor Relations

Investor Relations

Sophiris Bio Inc. is a late-stage biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is ready to move into Phase 3 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH).

Stock Quote





Copyright Nasdaq. Minimum 15 minutes delayed.

Data Provided by Refinitiv. Minimum 15 minutes delayed.